HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.
Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting with Processa management, please contact Yvonne Briggs at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at www.processapharma.com.
Company Contact:
Patrick Lin
(925) 683-3218
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.20 |
Daily Change: | 0.0065 3.45 |
Daily Volume: | 2,848,002 |
Market Cap: | US$638K |
May 30, 2025 April 15, 2025 March 18, 2025 January 30, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load